Ting-Ting Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ting-Ting Zeng has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Chen Jiang
State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou 510060 P. R. China
16 shared publications - Dan Xie
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center , Guangzhou 510060
16 shared publications - Jiarong Zhan
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
16 shared publications - Jun Liu
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
16 shared publications - Lei Li
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China
16 shared publications - Mengqing Li
Department Of Pathology, Peking University Shenzhen Hospital, Shenzhen, China
16 shared publications
Latest Publications
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S9 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
LTBP2 neutralization enhances paclitaxel sensitivity in vitro and in vivo
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S9 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
LTBP2 neutralization enhances paclitaxel sensitivity in vitro and in vivo
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
Cox proportional hazard regression analyses for overall survival
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
Cox proportional hazard regression analyses for overall survival
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
Cox proportional hazard regression analyses for progressive free survival
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
Cox proportional hazard regression analyses for progressive free survival
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
CAF-derived LTBP2 promotes proliferation and migration in CAFs and enhances migration and chemoresistance in ESCC cells
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
CAF-derived LTBP2 promotes proliferation and migration in CAFs and enhances migration and chemoresistance in ESCC cells
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
Integrated analysis of LTBP2 expression
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
Integrated analysis of LTBP2 expression
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S10 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
Flow cytometry analysis of bone marrow cells in mice under combination treatments
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S10 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
Flow cytometry analysis of bone marrow cells in mice under combination treatments
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S6 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
LTBP2 promotes migration and chemoresistance in ESCC cells independent of TGF-β1 signaling
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S6 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
LTBP2 promotes migration and chemoresistance in ESCC cells independent of TGF-β1 signaling
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S7 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
Anti–integrin α6 or anti–integrin β4 antibody treatment mitigates ESCC cell migration and enhances chemotherapy sensitivity
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S7 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
Anti–integrin α6 or anti–integrin β4 antibody treatment mitigates ESCC cell migration and enhances chemotherapy sensitivity
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
Association of LTBP2 expression with clinicopathological features in ESCC
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
Association of LTBP2 expression with clinicopathological features in ESCC
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
Dose-dependent effects of LTBP2 on migration and chemoresistance in ESCC cells
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5 from Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
Dose-dependent effects of LTBP2 on migration and chemoresistance in ESCC cells